Gastric Balloon — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

The gastric balloon (intragastric balloon, IGB) is a non-surgical, reversible weight loss intervention in which a deflated silicone balloon is introduced into the stomach via endoscopy and inflated with saline solution — typically 400–700 mL — to occupy a significant portion of the gastric volume. By physically reducing the functional capacity of the stomach, the balloon promotes early satiety, reduces hunger, and limits meal portion size, facilitating caloric restriction. Unlike bariatric surgery (gastric bypass, sleeve gastrectomy), no incisions or stapling of the stomach are involved; the procedure is entirely reversible and the balloon is removed at 6 months. Two principal balloon systems are in clinical use: the fluid-filled balloon (Orbera, Spatz) inflated with saline, often with methylene blue dye added to detect spontaneous deflation via urine colour change; and the gas-filled swallowable capsule balloon (Elipse), which does not require endoscopy for placement and passes naturally after approximately 16 weeks when an internal valve opens. Gastric balloon therapy is not a standalone treatment; it is effective only when embedded within a structured multidisciplinary programme of dietary counselling, physical activity coaching, and behavioural therapy that continues throughout the 6 months of balloon placement and beyond removal.

The gastric balloon is indicated for adults with a BMI of 30–40 kg/m² who have not achieved adequate weight loss through dietary and lifestyle interventions alone, or for adults with BMI above 40 who prefer a non-surgical approach or are not yet surgical candidates. It is also used as a pre-operative weight loss strategy for patients with BMI above 50 or severe obesity-related comorbidities before planned bariatric surgery, to reduce operative risk by achieving 10–15% pre-surgical weight reduction. Specific obesity-related conditions that may benefit from the weight loss achieved include type 2 diabetes with suboptimal glycaemic control, obstructive sleep apnoea, hypertension, non-alcoholic fatty liver disease (NAFLD), and knee or hip osteoarthritis where excess weight worsens symptoms. Contraindications are carefully screened at the pre-procedure assessment and include: prior gastric or oesophageal surgery that has altered gastric anatomy (sleeve gastrectomy, gastric bypass, Nissen fundoplication); large hiatus hernia (greater than 5 cm), which risks balloon herniation into the thorax; known or suspected oesophageal varices, active peptic ulcer, gastric cancer, or coagulopathy; current pregnancy or breastfeeding; active inflammatory bowel disease; a current prescription of anticoagulants or antiplatelet therapy; alcohol or substance dependence; and significant psychiatric comorbidity not stable on treatment.

The placement procedure is performed under conscious sedation in an endoscopy unit. The patient fasts for 6 hours beforehand. Before balloon insertion, a diagnostic upper endoscopy is performed to confirm the absence of contraindications (active ulcers, large hiatus hernia, oesophageal varices, or prior surgical scars). If the stomach is clear, the deflated silicone balloon is introduced through the mouth on a specially designed delivery catheter, advanced into the gastric body under direct endoscopic vision, and positioned in the body of the stomach below the gastro-oesophageal junction. The balloon is then inflated by injecting 400–700 mL of sterile saline through the catheter (the exact volume depends on the patient's stomach size and the balloon system used). A small amount of methylene blue dye is mixed with the saline in most systems — if the balloon deflates spontaneously, dye absorbed from the gut turns urine green, alerting the patient to seek urgent assessment. Once inflated, the fill tube is released with a self-sealing valve and the catheter and endoscope are removed. The patient recovers in a monitored area for 30–60 minutes. The balloon is removed at 6 months using a similar endoscopic procedure: a needle punctures the balloon to deflate it, and it is retrieved through the mouth using grasping forceps, again under conscious sedation.

Gastric balloon therapy achieves clinically meaningful weight loss when combined with dietary and lifestyle support. Clinical trials and systematic reviews report average total body weight loss (TBWL) of 10–15% over 6 months — equivalent to 25–35% of excess body weight — compared to 3–5% TBWL with dietary counselling alone. A 2016 meta-analysis of 68 studies including over 6,000 patients reported mean excess weight loss of 38%. Associated metabolic improvements include reductions in fasting glucose (HbA1c reduction of 0.3–0.6%), blood pressure (mean reduction 5–10 mmHg systolic), and total cholesterol. Non-alcoholic fatty liver disease improves in proportion to weight lost, with histological improvement seen in patients losing 10% or more TBWL. For pre-surgical patients, gastric balloon-facilitated weight loss reduces anaesthetic risk, operative time, and perioperative complications in subsequent bariatric surgery. Quality of life scores improve significantly during balloon treatment. The key limitation of the gastric balloon is weight regain after removal: without sustained lifestyle changes, most patients regain 25–50% of lost weight within 12 months of balloon removal, underscoring that the balloon is a tool to facilitate behaviour change, not a permanent treatment.

Gastric balloon placement carries both common expected effects and rare serious complications. Nausea, vomiting, and abdominal cramping are virtually universal in the first 3–7 days as the stomach adapts to the sudden presence of the balloon; managed with antiemetic medication (ondansetron, metoclopramide), proton pump inhibitors, and dietary guidance. A liquid diet is maintained for the first 2–7 days. Spontaneous balloon deflation occurs in approximately 2–7% of cases; if accompanied by methylene blue dye, urine turns green — the patient must be assessed urgently, as a deflated balloon can migrate to the small intestine causing obstruction (rare but potentially life-threatening). Balloon migration requiring endoscopic or surgical retrieval occurs in under 1%. Gastric ulceration develops in approximately 2–5% of patients, particularly with larger balloon volumes, and is reduced by prophylactic PPI therapy throughout the 6 months. Oesophageal or gastric perforation during placement or removal is extremely rare (under 0.1%). Intolerance to the balloon requiring early removal — due to persistent nausea, pain, or patient distress — occurs in 5–10%. Renal or liver failure has been rarely reported as a serious adverse event in published safety reviews of older balloon systems. Balloon-related mortality is estimated at approximately 0.01–0.02%.

The first 3–7 days after balloon placement are the most challenging: most patients experience significant nausea, vomiting, and abdominal cramping during stomach adjustment. Pre-emptive prescription of antiemetics (ondansetron and domperidone or metoclopramide) and a PPI (omeprazole 20 mg daily throughout balloon treatment) are standard practice. A clear liquid diet progresses to full liquids over the first 2–3 days, then soft foods at 1–2 weeks, and a structured reduced-calorie diet from week 2 onwards. Weight loss is most rapid in the first 6–8 weeks and slows thereafter. Monthly visits with a dietitian and, ideally, a bariatric psychologist are recommended throughout the 6-month treatment period to maximise and sustain weight loss. Physical activity is gradually increased from gentle walking initially to moderate aerobic activity (30 minutes most days) by week 3–4. Alcohol is strongly discouraged during balloon therapy due to gastric irritation risk and caloric density. At 6 months, balloon removal is planned; a post-removal dietary and lifestyle programme is essential to prevent weight regain. Approximately 30–50% of patients who complete the full programme and maintain lifestyle changes demonstrate sustained weight loss at 12 months post-removal.